Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 11/20 | 0.65 |
| ▸ | MAPT | P10636 | 9/20 | 0.65 |
| ▸ | RAB9A | P51151 | 5/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.64 |
| ▸ | GFER | P55789 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | DEPTOR | Q8TB45 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4904052 | 1.00 | GAA (0.65) | GAAMAPTRAB9AALDH1A1GFER | |
| SCHEMBL4904047 | 1.00 | GAA (0.65) | GAAMAPTRAB9AALDH1A1GFER | |
| SCHEMBL14366540 | 0.98 | MAPT (0.66) | GAAMAPTRAB9AALDH1A1GFER | |
| SCHEMBL5239005 | 0.98 | MAPT (0.66) | GAAMAPTRAB9AALDH1A1GFER | |
| SCHEMBL5240047 | 0.98 | MAPT (0.66) | GAAMAPTRAB9AALDH1A1GFER | |
| SCHEMBL4238950 | 0.82 | GAA (0.65) | GAAMAPTRAB9AALDH1A1GFER | |
| SCHEMBL21114872 | 0.82 | MAPT (0.65) | GAAMAPTRAB9AALDH1A1GFER | |
| SCHEMBL21114874 | 0.82 | MAPT (0.65) | GAAMAPTRAB9AALDH1A1GFER | |
| SCHEMBL21114859 | 0.82 | ALDH1A1 (0.65) | GAAMAPTRAB9AALDH1A1GFER | |
| SCHEMBL21114857 | 0.82 | ALDH1A1 (0.65) | GAAMAPTRAB9AALDH1A1GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622494-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090170923-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-02 | — | — | US | disclosed |
| US-20090170906-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-02 | — | — | US | disclosed |
| US-20090156621-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-06-18 | — | — | US | disclosed |
| US-7419997-B2 | Tetrahydrocarbazole derivatives and their pharmaceutical use | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
| US-7351733-B2 | Tetrahydrocarbazole derivatives and their pharmaceutical use | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351733-B2 | Tetrahydrocarbazole derivatives and their pharmaceutical use | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-01 | — | — | US | disclosed |
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170906-A1 | HCV INHIBITORS | HAVCR2, MAVS, EIF2AK2 | GAA 908/4885MAPT 1187/4885RAB9A 1647/4885 |
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | MAVS, SARS1, ZC3HAV1 | GAA 1417/4885MAPT 3817/4885RAB9A 2512/4885 |
| US-20090156621-A1 | HCV INHIBITORS | HAVCR2, MAVS, EIF2AK2 | GAA 908/4885MAPT 1187/4885RAB9A 1647/4885 |
| US-20090170923-A1 | HCV INHIBITORS | HAVCR2, MAVS, EIF2AK2 | GAA 908/4885MAPT 1187/4885RAB9A 1647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.